Literature DB >> 11682143

Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.

S Nishino1, N Fujiki, B Ripley, E Sakurai, M Kato, T Watanabe, E Mignot, K Yanai.   

Abstract

A growing amount of evidence suggests that a deficiency in hypocretin/orexin neurotransmission is critically involved in animal and human forms of narcolepsy. Since hypocretin-containing neurons innervate and excite histaminergic tuberomammillary neurons, altered histaminergic neurotransmission may also be involved in narcolepsy. We found a significant decrease in histamine content in the cortex and thalamus, two structures important for histamine-mediated cortical arousal, in Hcrtr-2 mutated narcoleptic Dobermans. In contrast, dopamine and norepinephrine contents in these structures were elevated in narcoleptic animals, a finding consistent with our hypothesis of altered catecholaminergic transmission in these animals. Considering the fact that histamine promotes wakefulness, decreases in histaminergic neurotransmission may also account for the sleep abnormalities in hypocretin-deficient narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682143     DOI: 10.1016/s0304-3940(01)02270-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

Review 1.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions.

Authors:  Matthew E Carter; Antoine Adamantidis; Hiroshi Ohtsu; Karl Deisseroth; Luis de Lecea
Journal:  J Neurosci       Date:  2009-09-02       Impact factor: 6.167

Review 3.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

4.  CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.

Authors:  Takashi Kanbayashi; Tohru Kodama; Hideaki Kondo; Shinsuke Satoh; Yuichi Inoue; Shigeru Chiba; Tetsuo Shimizu; Seiji Nishino
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

5.  Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.

Authors:  Seiji Nishino; Eiko Sakurai; Sona Nevsimalova; Yasushi Yoshida; Takehiko Watanabe; Kazuhiko Yanai; Emmanuel Mignot
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 6.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

7.  Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.

Authors:  Michihiro Mieda; Jon T Willie; Junko Hara; Christopher M Sinton; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-16       Impact factor: 11.205

8.  Identification of the variations in the CPT1B and CHKB genes along with the HLA-DQB1*06:02 allele in Turkish narcolepsy patients and healthy persons.

Authors:  Sultan Cingoz; Sinem Agilkaya; Ibrahim Oztura; Secil Eroglu; Derya Karadeniz; Ahmet Evlice; Oguz Altungoz; Hikmet Yilmaz; Baris Baklan
Journal:  Genet Test Mol Biomarkers       Date:  2014-02-26

9.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

10.  Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models.

Authors:  Christelle Anaclet; Régis Parmentier; Koliane Ouk; Gérard Guidon; Colette Buda; Jean-Pierre Sastre; Hidéo Akaoka; Olga A Sergeeva; Masashi Yanagisawa; Hiroshi Ohtsu; Patricia Franco; Helmut L Haas; Jian-Sheng Lin
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.